Asterias Biotherapeutics (AST) Announces FDA Clearance to Enroll C-4 Patients in SCiStar Study
Tweet Send to a Friend
Asterias Biotherapeutics, Inc. (NYSE: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that the U.S ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE